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Methylprednisolone 
Results
All the patients in our study had complete relief of symptoms within 48 hours of the first intramuscular injection of methylprednisolone. Table 1 shows that there were highly significant decreases in morning stiffness and visual analogue scale and a significant and sustained increase in haemoglobin with treatment. The erythrocyte sedimentation rate also showed a significant and sustained decrease; figure 1 shows the gradual decrease in erythrocyte sedimentation rate over the first 12 weeks. The immunoglobulin concentrations were normal at onset apart from two patients-these returned to normal with treatment. The diurnal cortisol rhythm (at 0900 and midnight) was preserved in all patients after 12 weeks of treatment. There were normal increases of 1 -deoxycortisol concentrations after the metyrapone test-this suggests normal function of the hypothalamic pituitary adrenal axis in the seven patients in whom this test was performed. Immunofluorescence analysis showed a marked decrease in the concentrations of the CD8 (supressor/cytotoxic) subset in the peripheral blood of eight of nine patients Figure 2 shows the release profile for the intramuscular injection of 120 mg of methylprednisolone in five patients determined by high performance liquid chromatography. There was a concentration peak at 6-8 hours of 43 end of one year all patients in the study were receiving a monthly injection of 40-60 mg of methylprednisolone. This treatment was acceptable, well tolerated, and showed no local or systemic side effects apart from minor bruising in three patients. The patients received injections at the outpatient clinic, although it is feasible for patients to receive intramuscular injections of methylprednisolone regularly at a general practitioner's surgery; this treatment also ensures compliance.
Over the first 12 weeks the cumulative dose of methylprednisolone administered was 480 mg (equivalent to 600 mg of prednisolone). In contrast, if an average daily dose of 10 mg of prednisolone is assumed in the conventional treatment of polymyalgia rheumatica (it is often higher), then the cumulative dose at 12 weeks would be 840 mg-that is, 40% greater than that for the intramuscular injection of methylprednisolone. This difference between the cumulative dose of prednisolone given by mouth and the intramuscular injection of methylprednisolone is further accentuated during maintenance treatment. For example, at 12 months all our patients were receiving 40-60 mg of methylprednisolone each month-that is 1 -7-2 5 mg of prednisolone daily.
Various studies have reported different incidences of steroid side effects in the treatment of polymyalgia rheumatica. Most, including a recent study by Kyle and Hazleman,2 have shown that steroid side effects occur in proportion to the total steroid dose administered.24 Our study suggests that with the intramuscular injection of methylprednisolone it is possible to maintain disease remission with a relatively small total intake of steroids. Whether this form of treatment results in fewer long term side effects needs to be established by a controlled trial.
It is encouraging that this regimen of steroid treatment preserves the normal response of the hypothalamic pituitary adrenal axis after 12 weeks of treatment. This may be related to the release profile of methylprednisolone injected intramuscularly. As shown in our study of the release of 120 mg of methylprednisolone and in the manufacturer's data for the release of 40 mg of methylprednisolone injected intramuscularly (figure 2), there is an early peak between six and eight hours followed by a relatively rapid decline over the first week. Thereafter there is a much slower decrease in weeks two and three. This gradually decreasing concentration of the drug probably accounts for the sustained therapeutic effect while allowing the full recovery of the hypothalamic pituitary adrenal axis before the next injection. Although the hypothalamic pituitary adrenal axis has not been investigated during steroid treatment by mouth in polymyalgia rheumatica, there is evidence that such treatment in other rheumatic and non-rheumatic diseases does cause hypothalamic pituitary adrenal axis suppression.1' 12 Thus the lack of hypothalamic pituitary adrenal axis suppression may constitute an additional important advantage of the intramuscular injection of methylprednisolone over prednisolone given by mouth.
This avoidance of dependence on steroids may make the intramuscular injection of methylprednisolone, as used in our treatment regimen, an attractive alternative in many clinical situtations where conventionally low doses of prednisolone given by mouth are used.
It is interesting that although the concentrations of methylprednisolone in serum samples decrease to 8 ng/ml by day seven, adequate control of the disease is maintained for the next two to three weeks after a single intramuscular injection of 120 mg of methylprednisolone. Only at 48-72 hours before the next injection was a slight increase in muscle stiffness and pain found. Four such intramuscular injections of methylprednisolone were sufficient to cause a smooth reduction of erythrocyte sedimentation rate to normal values within the first 12 weeks (fig 1) . Corkill et al7, using a similar regimen in active rheumatoid arthritis, found that although there was a relative decrease in erythrocyte sedimentation rate in the group treated with steroids, the mean erythrocyte sedimentation rate never reached normal values. This dissimilar response to steroids in polymyalgia rheumatica and rheumatoid arthritis (often a differential diagnosis with its polymyalgic onset in the elderly) highlights the high sensitivity to steroids of the former disease.
The cause of this dissimilar response remains unexplained. Glucocorticoids act by binding to specific, cytosolic glucocorticoid receptors and there is in vitro and in vivo evidence that the cellular sensitivity to glucocorticoids may correlate with the activity and concentration of intracellular glucocorticoid receptors."3 14 Such a variation may be responsible for the difference in sensitivity to steroids in polymyalgia rheumatica and rheumatoid arthritis.
The low numbers of peripheral blood CD8+ lymphocytes in most of our patients are consistent with previous reports of such an immunoregulatory abnormality in polymyalgia rheumatica and giant cell arteritis.9 1S A study by Elling et al'6 determined the positive predictive value of a significantly low number of CD8+ T cells in polymyalgia rheumatica or giant cell arthritis to be 85% in 108 patients who had a temporal artery biopsy.
Having established that this regimen of the intramuscular injection of methylprednisolone is a safe, well tolerated, and yet an efficacious treatment for polymyalgia rheumatica, we now intend to evaluate the efficacy and metabolic side effects of this regimen compared with conventional doses of prednisolone given by mouth. We plan to carry out a prosective, controlled, randomised, and initially double blind study comparing the intramuscular injection of methylprednisolone with prednisolone given by mouth over two years for the treatment of polymyalgia rheumatica. An important aspect of the study will be to monitor carefully the extent of steroid induced osteoporosis by measuring the mineral density of bone in the two groups.
Although most studies identify osteopenia as the principal complication of long term steroid treatment, the true incidence of osteoporosis in such patients is unknown as there are few studies which report prospective data on bone density measurements.i7 The rate of steroid induced bone loss also remains to be determined, although one study suggests that there is rapid early loss and a plateau after about six months. 8 The question of whether different routes of steroid administration may result in different metabolic effects has not been studied before and a controlled study of methylprednisolone versus prednisolone given by mouth for two years will, it is hoped, go some way towards answering these questions. Such a study will also allow a longitudinal study of immunoregulatory abnormalities such as CD8 lymphopenia in patients with polymyalgia rheumatica.
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